{"id":1381,"date":"2020-05-26T08:00:00","date_gmt":"2020-05-26T06:00:00","guid":{"rendered":"http:\/\/invivo.partners\/?p=1381"},"modified":"2020-05-26T16:45:25","modified_gmt":"2020-05-26T14:45:25","slug":"una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures","status":"publish","type":"post","link":"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/","title":{"rendered":"Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d&#8217;euros d\u2019Invivo Ventures"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">L&#8217;Hospital Cl\u00ednic de Barcelona-IDIBAPS ha fundat Gyala Therapeutics, una nova spin-off centrada en desenvolupar noves ter\u00e0pies de CAR-T per al tractament de malalties hematol\u00f2giques malignes. Per finan\u00e7ar aquest projecte, la companyia ha obtingut 1,5 milions euros de capital inicial d\u2019Invivo Ventures, amb seu a Barcelona, \u200b\u200buna de les firmes biom\u00e8diques de capital risc l\u00edders a Espanya.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En aquesta spin-off hi col\u00b7laborar\u00e0 el Dr. <strong>Manel Juan<\/strong>, cap de Servei d&#8217;Immunologia del CDB del Cl\u00ednic i de el grup <a href=\"https:\/\/www.clinicbarcelona.org\/ca\/idibaps\/arees-de-recerca\/agressio-biologica-i-mecanismes-de-resposta\/immunogenetica-en-la-resposta-autoinflamatoria\" target=\"_blank\" rel=\"noreferrer noopener\">Inmunogen\u00e9tica i immunoter\u00e0pia de la resposta immune i autoinflamat\u00f2ria<\/a> de l&#8217;IDIBAPS, que s&#8217;encarregar\u00e0 de l&#8217;aven\u00e7 cient\u00edfic del programa, que t\u00e9 per objectiu desenvolupar una ter\u00e0pia CAR-T enfront d&#8217;una nova diana terap\u00e8utica. S&#8217;espera que el nou CAR-T es pugui arribar a provar en pacients a partir de 2022.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El CAR-T (limf\u00f2cits T amb receptor antig\u00e8nic quim\u00e8ric) \u00e9s un tipus de ter\u00e0pia g\u00e8nica que consisteix a modificar els limf\u00f2cits T &#8211; un tipus de gl\u00f2buls blancs responsables principals de la resposta immunit\u00e0ria &#8211; del propi pacient perqu\u00e8 tinguin la capacitat d&#8217;atacar les c\u00e8l\u00b7lules tumorals. Mitjan\u00e7ant l&#8217;af\u00e8resi (una t\u00e8cnica que permet la separaci\u00f3 dels components de la sang) s&#8217;obt\u00e9 una quantitat de limf\u00f2cits T que es reprogramen gen\u00e8ticament amb el receptor espec\u00edfic antitumoral, de manera que quan es transfonen de nou al pacient poden recon\u00e8ixer espec\u00edficament les c\u00e8l\u00b7lules tumorals i atacar-les. Diversos tipus de CAR-T han demostrat la seva efic\u00e0cia en el tractament de leuc\u00e8mies i limfomes B.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Manel Juan<\/strong> assenyala que, \u00ab<em>aquest projecte ens permetr\u00e0 avan\u00e7ar en el desenvolupament de noves ter\u00e0pies CAR-T per fer front a diferents neopl\u00e0sies limfoides i que puguin arribar de forma r\u00e0pida als nostres pacients<\/em>\u00ab.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El Dr. <strong>Elias Campo<\/strong>, director de Recerca de l\u2019Hospital Cl\u00ednic i director de l&#8217;IDIBAPS, explica : \u00ab<em>Les ter\u00e0pies basades en CAR-T han demostrat efic\u00e0cia en el tractament de certs tipus de leuc\u00e8mia i limfoma. Amb aquest nou impuls contribuirem a millorar el tractament d&#8217;aquest tipus de malalties<\/em>\u00ab<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El Dr. <strong>Josep M. Campistol<\/strong>, director general de l&#8217;Hospital Cl\u00ednic, i el Dr. <strong>Llu\u00eds Pareras<\/strong>, soci fundador d\u2019Invivo Ventures, han assenyalat en una declaraci\u00f3 conjunta: \u00ab<em>La Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica i Invivo Ventures anuncien que uneixen els seus esfor\u00e7os per desenvolupar una nova ter\u00e0pia basada en receptors d&#8217;antigen quim\u00e8rics (CAR-T) per tractar un greu tipus de c\u00e0ncer hematol\u00f2gic. Aquesta ter\u00e0pia t\u00e9 com a diana un antigen present a la superf\u00edcie de les c\u00e8l\u00b7lules tumorals a la que, fins ara, no se li havia prestat atenci\u00f3. Hi ha molt potencial en el nostre ecosistema d&#8217;investigaci\u00f3 i \u00e9s important que institucions acad\u00e8miques i de capital de risc treballin conjuntament amb l&#8217;objectiu de resoldre necessitats cl\u00edniques no cobertes i aportar valor a la societat<\/em>\u00ab.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Albert Ferrer<\/strong>, soci fundador d\u2019Invivo Ventures, explica que, \u00ab<em>Invivo t\u00e9 com a objectiu donar suport a la transfer\u00e8ncia de tecnologia des dels centres de recerca i hospitals espanyols i millorar el creixement i el desenvolupament de productes innovadors. La inversi\u00f3 en Gyala Therapeutics \u00e9s un clar exemple d&#8217;aquesta visi\u00f3 i estem particularment satisfets que permeti la creaci\u00f3 d&#8217;un nou negoci i la creaci\u00f3 de nous llocs de treball en aquest dif\u00edcil entorn econ\u00f2mic<\/em>\u00ab.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Governan\u00e7a<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Gyala Therapeutics impulsar\u00e0 aquest projecte a trav\u00e9s d&#8217;un acord de col\u00b7laboraci\u00f3 amb l&#8217;Hospital Cl\u00ednic-IDIBAPS, que es complementar\u00e0 amb els serveis de prove\u00efdors espanyols i internacionals.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El director general de la nova spin-off ser\u00e0 el Dr. <strong>Claudio Santos<\/strong>, que t\u00e9 experi\u00e8ncia en la creaci\u00f3 i inversi\u00f3 en companyies de les ci\u00e8ncies de la vida i en desenvolupament de negoci, tant en l&#8217;\u00e0mbit acad\u00e8mic com en la ind\u00fastria.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Llu\u00eds Pareras<\/strong> i <strong>Albert Ferrer<\/strong>, socis fundadors d\u2019Invivo Ventures, administrat per Invivo Capital Partners, s&#8217;uniran a el Consell d&#8217;Administraci\u00f3 de Gyala Therapeutics al costat de <strong>Rosa Vilavella<\/strong>, gerent de la Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica i de l&#8217;IDIBAPS.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sobre el Cl\u00ednic&nbsp;&nbsp;<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019Hospital Cl\u00ednic de Barcelona \u00e9s un hospital p\u00fablic universitari&nbsp;amb\u202funa hist\u00f2ria centen\u00e0ria. Amb una plantilla de 4.500 professionals, \u00e9s un dels principals centres d\u2019assist\u00e8ncia m\u00e8dica d\u2019Espanya&nbsp;i el primer en producci\u00f3 cient\u00edfica. Ofereix una assist\u00e8ncia de qualitat,&nbsp;una investigaci\u00f3 biom\u00e8dica del m\u00e0xim nivell competitiu i una gran dedicaci\u00f3 docent per formar professionals. Tot plegat s\u2019emmarca en l\u2019excel\u00b7l\u00e8ncia d\u2019una gesti\u00f3 equilibrada, amb l\u2019objectiu d\u2019oferir a la societat una medicina humanitzada d\u2019avantguarda.&nbsp;&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sobre&nbsp;l&#8217;IDIBAPS<\/strong>&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#8217;Institut&nbsp;d&#8217;Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) \u00e9s un centre de recerca d&#8217;excel\u00b7l\u00e8ncia que aborda malalties d&#8217;alta prevalen\u00e7a, morbiditat i mortalitat. Fundat el 1996, \u00e9s un consorci p\u00fablic integrat per la Generalitat de Catalunya, l&#8217;Hospital Cl\u00ednic de Barcelona, la Facultat de Medicina de la Universitat de Barcelona i&nbsp;l&#8217;Institut&nbsp;de Recerca Biom\u00e8dica de Barcelona del CSIC.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hi treballen m\u00e9s de mil professionals dedicats a la recerca que s\u2019organitzen en un centenar de grups d\u2019investigaci\u00f3. La combinaci\u00f3 de la recerca b\u00e0sica amb la cl\u00ednica permet transferir amb m\u00e9s efic\u00e0cia als pacients els aven\u00e7os cient\u00edfics obtinguts al laboratori. Amb prop de 1.100 articles publicats l\u2019any i un factor d\u2019impacte de m\u00e9s de 6.000 punts, \u00e9s el principal centre de recerca biom\u00e8dica de l\u2019Estat.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sobre Invivo Ventures<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Invivo Ventures FCR inverteix en companyies de ci\u00e8ncies de la vida\/atenci\u00f3 m\u00e8dica en una etapa primerenca i est\u00e0 administrat per Invivo Capital Partners, un fons de gesti\u00f3 fundat pel Dr. Llu\u00eds Pareras i Albert Ferrer. Tots dos gerents tenen una \u00e0mplia experi\u00e8ncia en el sector i tamb\u00e9 administren la firma de capital risc Healthequity SCR. Invivo Ventures FCR compta amb la participaci\u00f3 d&#8217;una majoria d&#8217;inversors privats i amb el suport de diversos inversors institucionals com el Fons Europeu d&#8217;Inversions, Fond-ICO Global, l&#8217;Institut Catal\u00e0 de Finances i l&#8217;Institut Valenci\u00e0 de Finances.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;Hospital Cl\u00ednic de Barcelona-IDIBAPS ha fundat Gyala Therapeutics, una nova spin-off centrada en desenvolupar noves ter\u00e0pies de CAR-T per al tractament de malalties hematol\u00f2giques malignes. Per finan\u00e7ar aquest projecte, la companyia ha obtingut 1,5 milions euros de capital inicial d\u2019Invivo Ventures, amb seu a Barcelona, \u200b\u200buna de les firmes biom\u00e8diques de capital risc l\u00edders a<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[516],"tags":[532,547,538,542,536,528,541,540,534,546],"class_list":["post-1381","post","type-post","status-publish","format-standard","hentry","category-noticias-ca","tag-albert-ferrer-ca","tag-fondo-inversion","tag-gyala-therapeutics","tag-inversion","tag-investment","tag-invivo-capital-ca","tag-invivo-ventures","tag-lluis-pareras","tag-luis-pareras-ca","tag-venture-capital"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d&#039;euros d\u2019Invivo Ventures - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d&#039;euros d\u2019Invivo Ventures - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"L&#8217;Hospital Cl\u00ednic de Barcelona-IDIBAPS ha fundat Gyala Therapeutics, una nova spin-off centrada en desenvolupar noves ter\u00e0pies de CAR-T per al tractament de malalties hematol\u00f2giques malignes. Per finan\u00e7ar aquest projecte, la companyia ha obtingut 1,5 milions euros de capital inicial d\u2019Invivo Ventures, amb seu a Barcelona, \u200b\u200buna de les firmes biom\u00e8diques de capital risc l\u00edders a\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-26T06:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-05-26T14:45:25+00:00\" \/>\n<meta name=\"author\" content=\"invivo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"invivo\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/\"},\"author\":{\"name\":\"invivo\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789\"},\"headline\":\"Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d&#8217;euros d\u2019Invivo Ventures\",\"datePublished\":\"2020-05-26T06:00:00+00:00\",\"dateModified\":\"2020-05-26T14:45:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/\"},\"wordCount\":1099,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"keywords\":[\"Albert Ferrer\",\"Fondo Inversi\u00f3n\",\"Gyala Therapeutics\",\"inversi\u00f3n\",\"investment\",\"Invivo capital\",\"Invivo Ventures\",\"Llu\u00eds Pareras\",\"Luis Pareras\",\"Venture Capital\"],\"articleSection\":[\"Noticias\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/\",\"url\":\"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/\",\"name\":\"Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d'euros d\u2019Invivo Ventures - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2020-05-26T06:00:00+00:00\",\"dateModified\":\"2020-05-26T14:45:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d&#8217;euros d\u2019Invivo Ventures\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789\",\"name\":\"invivo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g\",\"caption\":\"invivo\"},\"url\":\"https:\/\/invivo.partners\/ca\/author\/invivocapital\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d'euros d\u2019Invivo Ventures - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/","og_locale":"ca_ES","og_type":"article","og_title":"Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d'euros d\u2019Invivo Ventures - Invivo Partners","og_description":"L&#8217;Hospital Cl\u00ednic de Barcelona-IDIBAPS ha fundat Gyala Therapeutics, una nova spin-off centrada en desenvolupar noves ter\u00e0pies de CAR-T per al tractament de malalties hematol\u00f2giques malignes. Per finan\u00e7ar aquest projecte, la companyia ha obtingut 1,5 milions euros de capital inicial d\u2019Invivo Ventures, amb seu a Barcelona, \u200b\u200buna de les firmes biom\u00e8diques de capital risc l\u00edders a","og_url":"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/","og_site_name":"Invivo Partners","article_published_time":"2020-05-26T06:00:00+00:00","article_modified_time":"2020-05-26T14:45:25+00:00","author":"invivo","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"invivo","Temps estimat de lectura":"5 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/#article","isPartOf":{"@id":"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/"},"author":{"name":"invivo","@id":"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789"},"headline":"Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d&#8217;euros d\u2019Invivo Ventures","datePublished":"2020-05-26T06:00:00+00:00","dateModified":"2020-05-26T14:45:25+00:00","mainEntityOfPage":{"@id":"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/"},"wordCount":1099,"commentCount":0,"publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"keywords":["Albert Ferrer","Fondo Inversi\u00f3n","Gyala Therapeutics","inversi\u00f3n","investment","Invivo capital","Invivo Ventures","Llu\u00eds Pareras","Luis Pareras","Venture Capital"],"articleSection":["Noticias"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/","url":"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/","name":"Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d'euros d\u2019Invivo Ventures - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2020-05-26T06:00:00+00:00","dateModified":"2020-05-26T14:45:25+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/ca\/2020\/05\/26\/una-nova-spin-off-del-clinic-idibaps-de-immunoterapia-del-cancer-capta-una-inversio-de-15-milions-deuros-dinvivo-ventures\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/ca\/"},{"@type":"ListItem","position":2,"name":"Una nova spin-off del Cl\u00ednic-IDIBAPS de immunoter\u00e0pia del c\u00e0ncer capta una inversi\u00f3 de 1,5 milions d&#8217;euros d\u2019Invivo Ventures"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789","name":"invivo","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g","caption":"invivo"},"url":"https:\/\/invivo.partners\/ca\/author\/invivocapital\/"}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/1381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/comments?post=1381"}],"version-history":[{"count":3,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/1381\/revisions"}],"predecessor-version":[{"id":1408,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/1381\/revisions\/1408"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/media?parent=1381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/categories?post=1381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/tags?post=1381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}